Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01621243 · ClinicalTrials.gov registry record · Phase 1
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase 1 study, sponsored by Momenta Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT01621243 is a Phase 1 study that was terminated before completion, run by Momenta Pharmaceuticals. The registered enrollment target is 128 participants.
The verdict
NCT01621243, a Phase 1 study, was terminated before completion, sponsored by Momenta Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called necuparanib (M402). It is made from heparin, which is a well known blood thinner. Blood thinners have been shown in prior animal and human studies to have anti-cancer effects. Necuparanib has been re-engineered from heparin to have much lower blood thinning activity while keeping the anti-tumor activity. The investigators are testing whether necuparanib administered in combination with nab-paclitaxel and gemcitabine may be more effective than nab-paclitaxel and gemcitabine.
Interventions
- DRUG placebo
- DRUG nab-paclitaxel
- DRUG gemcitabine
- DRUG Necuparanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2012-05 |
| Est. Completion | 2016-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01621243
The ClinicalTrials.gov registry entry for NCT01621243 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Momenta Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01621243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01621243 about?
NCT01621243 is a clinical study titled "M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer". People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called necuparanib (M402). It is made from heparin, which is a well known blood thinner. Blood thinners have been shown in prior animal and human studies ...
What is the current status of trial NCT01621243?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2012-05. Estimated completion is 2016-10-24.
What interventions are being tested in trial NCT01621243?
The interventions under investigation include: placebo (DRUG), nab-paclitaxel (DRUG), gemcitabine (DRUG), Necuparanib (DRUG).
Who is sponsoring clinical trial NCT01621243?
This trial is sponsored by Momenta Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.